Dopamine replacement remediates risk aversion in Parkinson’s disease in a value-independent manner
Mariya V. Cherkasova, Jeffrey C. Corrow, Alisdair Taylor, Shanna C. Yeung, Jacob L. Stubbs, Martin J. McKeown, Silke Appel‐Cresswell, A. Jon Stoessl, Jason J.S. Barton
This study shows that dopamine replacement in Parkinson’s disease patients reduces risk aversion in a value-independent manner, while also increasing sensitivity to expected values.
Parkinsonism & Related Disorders · Aug 26, 2019Peer-reviewedNeuroscience